10-Q - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K/A - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

10-Q - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

8-K - Caribou Biosciences, Inc. (0001619856) (Filer)

BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in the following investor conferences: Citi's 2024 Global Healthcare Conference, Miami, FL December 3, 2024, panel at 2:30 PM ESTPanel title: Cell therapies in autoimmune disordersWebcast 7th Annual Evercore ISI HealthCONx Conference, Coral Gables, FLDecember 4, 2024, fireside chat at 10:25 AM ESTWebcast For more information, visit the Events page on Caribou's website. Webcasts will be available on the Caribou website fo

-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025 -- -- Continuing dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in r/r MM with higher lymphodepletion regimen following observations of efficacy; dose escalation data to be presented H1 2025 -- -- $281.0 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into H2 2026 -- BERKELEY, Calif., Nov. 06, 2024

BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024, which will be held November 14-19, 2024 in Washington, DC. The poster will highlight the preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance to evaluate CB-010 in the GALLOP Phase 1 clinical trial in patients with lupus nephritis (LN) and extrarenal lupus (ERL). Details of the poster presentation are as follows: Title:

-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track designations in B-NHL -- -- CB-010 GALLOP Phase 1 trial in patients with LN and ERL is on track to initiate by YE 2024 -- -- CB-012 AMpLify Phase 1 trial advancing in dose escalation -- BERKELEY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designations to CB-010 for refractory systemic lupus erythematosus (SLE

BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadership will participate in the following event and investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference, New York, NYSeptember 4, 2024 2024 Wells Fargo Healthcare Conference, Boston, MASeptember 5, 2024 During these conferences, Caribou leadership will conduct one-on-one meetings with investors registered. For more information, visit the Events page on Caribou's website. About Caribou's novel next-generation CRISPR platformCRISPR genome editing uses easily designed, mod

-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clin

-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; clinical data reports planned for 2024 and H1 2025 -- -- Enrolling 2L LBCL and prior CD19 relapsed LBCL patients based on CB-010 ANTLER Phase 1 data presented at 2024 ASCO Annual Meeting; data to be presented H1 2025 -- -- $311.8 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into H2 2026; cash runway extension of at least 6 months versus prior guidance -- BERKELEY, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported

-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Med

-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation of improved outcomes in partially HLA matched cohort -- -- Off-the-shelf CB-010 is partially HLA matched to patient within current screening timelines -- -- KOL webcast discussion of data from 46

BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's participation in the following event and investor conferences: • Caribou's webcast of KOL discussion from 2024 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2024, CB-010 ANTLER Phase 1 clinical trial data in r/r B-NHL to be shared in a press release at 6:00 pm CDT followed by a live webcast of a discussion with KOLs and management at 7:00 pm CDT. The presenters will include: Boyu Hu, MD, director of lymphoma and CLL in the division of hematology and hematologic malignancies,

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

SC 13G/A - Caribou Biosciences, Inc. (0001619856) (Subject)

In the last three months, 4 analysts have published ratings on Caribou Biosciences (NASDAQ:CRBU), offering a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $15.25, a high estimate of $24.00, and a low estimate of $9.00. This current average represents a 19.74%

HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $9 price target.

- Reuters 

During the last three months, 5 analysts shared their evaluations of Caribou Biosciences (NASDAQ:CRBU), revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.0, a high estimate of $24.00, and a lo

HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $24 to $9.

Gainers Structure Therapeutics (NASDAQ:GPCR) stock moved upwards by 71.0% to $58.47 during Monday's regular session. The market value of their outstanding shares is at $2.7 billion. Concord Medical Services (NYSE:CCM) stock rose 55.96% to $0.78. The company's market cap stands at $33.8 million. Microbot Medical (NASDAQ:MBOT) shares moved upwards by 40.79% to $1.41. The market value of their outstanding shares is at $20.2 million. Bio-Path Hldgs (NASDAQ:BPTH) shares moved upwards by 38.0% to $2.84. The market value of their outstanding shares is at $4.7 million. Olema Pharmaceuticals (NASDAQ:OLMA) shares rose 23.45% to $11.95. The market value of their outstanding shares is at $668.4 mil

At the RBC Global Healthcare Conference, held on 14-15 May, RBC’s Healthcare Desk Sector Strategist gauged biotech investor sentiment in an interview with Biotech TV. The strategist, Chris McCarthy, says he is trying to figure out investment sentiment and positioning. When asked about what he heard in the conference hallways, Chris said biotech investors are focused on the upcoming binary catalysts. Chris McCarthy highlighted some companies that have upcoming data readouts.  He adds that with data readouts, the investors see outsized stock moves, and they should start focusing on these companies as the readouts approach, including:  Agios Pharmaceuticals Inc (NASDAQ:AGIO): Tw

Ratings for Caribou Biosciences (NASDAQ:CRBU) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Caribou Biosciences, presenting an average target of $21.5, a high estimate of $24.00, and a low estimate of $19.00. A decline of 6.5

Evercore ISI downgraded Caribou Biosciences from Outperform to In-line and set a new price target of $3.00 from $13.00 previously

Cantor Fitzgerald initiated coverage of Caribou Biosciences with a rating of Neutral

Evercore ISI initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $13.00

Truist initiated coverage of Caribou Biosciences with a rating of Buy and set a new price target of $23.00

RBC Capital initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $22.00

Brookline Capital initiated coverage of Caribou Biosciences with a rating of Buy and set a new price target of $19.00

Oppenheimer initiated coverage of Caribou Biosciences with a rating of Outperform and set a new price target of $36.00

H.C. Wainwright initiated coverage of Caribou Biosciences with a rating of Buy and set a new price target of $28.00

Citigroup upgraded Caribou Biosciences from Neutral to Buy and set a new price target of $27.00

Citigroup initiated coverage of Caribou Biosciences with a rating of Neutral and set a new price target of $27.00

-- Highly-experienced hematologist and oncologist with proven track record successfully driving global clinical development of CAR-T cell therapies -- BERKELEY, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Tina Albertson, MD, PhD, as chief medical officer. Dr. Albertson brings 15 years of experience leading clinical drug development of cellular therapies and biologics. She will be responsible for strategic leadership of the clinical, regulatory, and medical affairs functions, and provide medical and operational leadership of Caribou's four clin

-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Terri Laufer, MD, to its scientific advisory board. Dr. Laufer is a leading rheumatologist known for her extensive research into immune cell regulation and dysfunction that leads to autoimmune diseases. She is an emeritus associate professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and an attending rheumatologist at the Penn Presbyterian Med

-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board. With four decades of experience, Dr. Jagannath is a renowned expert in bone marrow transplantation and treating patients with multiple myeloma, and he is the director of the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and professor of medicine, hematology and medical oncology, at Mount Sinai School of Medicine, New Yo

BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Reigin Zawadzki to the newly created position of chief people officer. Ms. Zawadzki brings over 20 years of experience leading human resources in the biotechnology industry. She will lead Caribou's people strategy and report to Rachel Haurwitz, PhD, president and chief executive officer. "Reigin is an experienced human resources leader who has an impressive track record in leading human resource strategies that are closely aligned with the mission, values, and culture of an organization,"

-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Stephen J. Schuster, MD, to its scientific advisory board (SAB). Dr. Schuster is an expert in treating patients with lymphoma and developing novel treatments, including pioneering the development of chimeric antigen receptor (CAR)-T cell therapies. "It's an honor to have Dr. Schuster join our SAB. Dr. Schuster is a highly esteemed global leader in the lymphoma field and played an integral part

BERKELEY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of David L. Johnson to its board of directors. Mr. Johnson is a seasoned executive with 30 years of commercial and operational experience in the biopharmaceutical industry. "David has an impressive record of successfully building commercial infrastructure and launching new medicines for patients," said Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer. "We are delighted to welcome him to our board of directors and look forward to benefitting from his expertise as we contin

-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL -- -- 2022 submission of IND application planned for CB-011, an allogeneic cell therapy candidate for patients with r/r multiple myeloma -- -- Leadership team expanded with appointment of Syed Rizvi, M.D., as chief medical officer -- -- Cash, cash equivalents, and marketable securities of $413.5 million as of December 31, 2021 support advancement of wholly owned pipeline of allogeneic CAR-T and CAR-NK cell therapies -- BERKELEY, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU),

BERKELEY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Syed Rizvi, M.D., to the newly created position of chief medical officer. Dr. Rizvi has more than two decades of experience in all stages of drug development, from clinical strategy and execution through regulatory submissions to support approval and commercialization of several cancer treatments, including two autologous CAR-T cell therapies ABECMA® and BREYANZI®. "Syed's extensive industry knowledge, strategic insight, and significant leadership experience in the development of oncology c

BERKELEY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointments of Dara Richardson-Heron, M.D., to its board of directors and Ruhi Khan as its chief business officer. Dr. Richardson-Heron has more than 25 years of leadership experience in the healthcare, corporate, nonprofit, and government sectors. Ms. Khan brings over 20 years of business development and investment management experience focused on the biotechnology and pharmaceutical industries. "Dara and Ruhi join Caribou at an exciting time as we advance our four wholly-owned allogeneic cell thera

BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed Ran Zheng to its board of directors. Ms. Zheng brings over 25 years of biotechnology industry leadership experience in biologics drug development with broad expertise in technical operations and the manufacture of gene and cell therapies.     "It is my pleasure to welcome Ran to our board of directors," said Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer. "Ran brings a wealth of strategic and operational expertise in the development of gene and cell therapies, from e